New drug cocktail shows promise for Tough-to-Treat myeloma

NCT ID NCT01665794

Completed Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of three drugs (pomalidomide, dexamethasone, and carfilzomib) in 25 people with multiple myeloma that had come back or stopped responding to prior treatments. The goal was to find the safest dose and see how well the drugs worked together to control the cancer. While the treatment aims to shrink tumors, it is not a cure, and patients may need ongoing therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
University Health Network - Princess Margaret Cancer Center

Toronto, Ontario, MISG 2M9, Canada
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637-1470, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States
Wayne State University - Karmonos Cancer Center

Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.